Vericel (NASDAQ:VCEL) Rating Lowered to Sell at StockNews.com

by · The Cerbat Gem

Vericel (NASDAQ:VCEL – Get Free Report) was downgraded by StockNews.com from a “hold” rating to a “sell” rating in a report released on Tuesday.

VCEL has been the subject of several other reports. TD Cowen increased their target price on Vericel from $55.00 to $60.00 and gave the company a “buy” rating in a research note on Tuesday, August 27th. Stephens upped their target price on shares of Vericel from $56.00 to $58.00 and gave the company an “overweight” rating in a research note on Friday, August 2nd. Canaccord Genuity Group began coverage on Vericel in a research note on Friday, August 9th. They issued a “buy” rating and a $57.00 price target for the company. Canaccord Genuity Group started coverage on Vericel in a research note on Friday, August 9th. They set a “buy” rating and a $57.00 price objective on the stock. Finally, Truist Financial lifted their target price on Vericel from $56.00 to $57.00 and gave the stock a “buy” rating in a research report on Tuesday, July 16th. One equities research analyst has rated the stock with a sell rating and nine have assigned a buy rating to the stock. According to data from MarketBeat.com, Vericel has an average rating of “Moderate Buy” and an average target price of $55.75.

Check Out Our Latest Research Report on Vericel

Vericel Trading Down 1.0 %

NASDAQ VCEL opened at $40.95 on Tuesday. The stock has a market cap of $1.99 billion, a P/E ratio of -4,095.00 and a beta of 1.67. The company’s fifty day simple moving average is $46.16 and its 200-day simple moving average is $47.23. Vericel has a 52 week low of $30.18 and a 52 week high of $54.10.

Vericel (NASDAQ:VCEL – Get Free Report) last issued its quarterly earnings data on Thursday, August 1st. The biotechnology company reported ($0.10) EPS for the quarter, hitting analysts’ consensus estimates of ($0.10). Vericel had a net margin of 0.37% and a return on equity of 0.35%. The firm had revenue of $52.70 million for the quarter, compared to analyst estimates of $52.59 million. During the same quarter in the previous year, the business posted ($0.11) EPS. The firm’s revenue was up 14.8% compared to the same quarter last year. On average, research analysts expect that Vericel will post 0.12 EPS for the current fiscal year.

Insider Activity

In other Vericel news, insider Sean C. Flynn sold 15,000 shares of the stock in a transaction on Tuesday, July 16th. The stock was sold at an average price of $52.18, for a total value of $782,700.00. Following the sale, the insider now directly owns 707 shares of the company’s stock, valued at $36,891.26. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In other Vericel news, insider Sean C. Flynn sold 15,000 shares of the company’s stock in a transaction dated Tuesday, July 16th. The shares were sold at an average price of $52.18, for a total value of $782,700.00. Following the completion of the transaction, the insider now owns 707 shares in the company, valued at approximately $36,891.26. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Joseph Anthony Mara, Jr. sold 5,000 shares of Vericel stock in a transaction that occurred on Friday, July 12th. The shares were sold at an average price of $50.00, for a total value of $250,000.00. Following the sale, the chief financial officer now directly owns 14,436 shares in the company, valued at approximately $721,800. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 43,333 shares of company stock valued at $2,167,562. 5.20% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the business. Juncture Wealth Strategies LLC lifted its holdings in Vericel by 48.1% in the third quarter. Juncture Wealth Strategies LLC now owns 11,643 shares of the biotechnology company’s stock worth $492,000 after purchasing an additional 3,783 shares during the period. Handelsbanken Fonder AB lifted its stake in shares of Vericel by 24.0% in the 3rd quarter. Handelsbanken Fonder AB now owns 15,479 shares of the biotechnology company’s stock worth $654,000 after acquiring an additional 3,000 shares during the period. SG Americas Securities LLC boosted its holdings in shares of Vericel by 106.1% in the third quarter. SG Americas Securities LLC now owns 24,486 shares of the biotechnology company’s stock valued at $1,035,000 after acquiring an additional 12,605 shares in the last quarter. Northwestern Mutual Wealth Management Co. increased its stake in shares of Vericel by 104.9% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 4,108 shares of the biotechnology company’s stock valued at $188,000 after acquiring an additional 2,103 shares during the period. Finally, Algert Global LLC bought a new stake in Vericel during the second quarter worth approximately $213,000.

About Vericel

(Get Free Report)

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.

Recommended Stories